Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatmen...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Korkmaz, T. [verfasserIn] Seber, S. [verfasserIn] Kefeli, U. [verfasserIn] Sari, E. [verfasserIn] Canhoroz, M. [verfasserIn] Oven, B. [verfasserIn] Yildirim, E. [verfasserIn] Yasar, N. [verfasserIn] Aydin, D. [verfasserIn] Balvan, O. [verfasserIn] Sener, N. [verfasserIn] Yuksel, S. [verfasserIn] Mert, A. [verfasserIn] Polat, O. [verfasserIn] Yumuk, F. [verfasserIn] Kanat, O. [verfasserIn] Gumus, M. [verfasserIn] Turhal, N. S. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2012

Schlagwörter:	Platinum sensitive disease Platinum refracter disease Second-line chemotherapy Small cell lung cancer

Übergeordnetes Werk:	Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 15(2012), 7 vom: 10. Nov., Seite 535-540
Übergeordnetes Werk:	volume:15 ; year:2012 ; number:7 ; day:10 ; month:11 ; pages:535-540

Links:	Volltext

DOI / URN:	10.1007/s12094-012-0960-6

Katalog-ID:	SPR02426041X

Internformat


LEADER	01000caa a22002652 4500
001	SPR02426041X
003	DE-627
005	20230519164619.0
007	cr uuu---uuuuu
008	201006s2012 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12094-012-0960-6 \|2 doi
035			\|a (DE-627)SPR02426041X
035			\|a (SPR)s12094-012-0960-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Korkmaz, T. \|e verfasserin \|4 aut
245	1	0	\|a Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
264		1	\|c 2012
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
650		4	\|a Platinum sensitive disease \|7 (dpeaa)DE-He213
650		4	\|a Platinum refracter disease \|7 (dpeaa)DE-He213
650		4	\|a Second-line chemotherapy \|7 (dpeaa)DE-He213
650		4	\|a Small cell lung cancer \|7 (dpeaa)DE-He213
700	1		\|a Seber, S. \|e verfasserin \|4 aut
700	1		\|a Kefeli, U. \|e verfasserin \|4 aut
700	1		\|a Sari, E. \|e verfasserin \|4 aut
700	1		\|a Canhoroz, M. \|e verfasserin \|4 aut
700	1		\|a Oven, B. \|e verfasserin \|4 aut
700	1		\|a Yildirim, E. \|e verfasserin \|4 aut
700	1		\|a Yasar, N. \|e verfasserin \|4 aut
700	1		\|a Aydin, D. \|e verfasserin \|4 aut
700	1		\|a Balvan, O. \|e verfasserin \|4 aut
700	1		\|a Sener, N. \|e verfasserin \|4 aut
700	1		\|a Yuksel, S. \|e verfasserin \|4 aut
700	1		\|a Mert, A. \|e verfasserin \|4 aut
700	1		\|a Polat, O. \|e verfasserin \|4 aut
700	1		\|a Yumuk, F. \|e verfasserin \|4 aut
700	1		\|a Kanat, O. \|e verfasserin \|4 aut
700	1		\|a Gumus, M. \|e verfasserin \|4 aut
700	1		\|a Turhal, N. S. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Revista de oncología \|d Barcelona : Doyma, 2000 \|g 15(2012), 7 vom: 10. Nov., Seite 535-540 \|w (DE-627)385985452 \|w (DE-600)2143451-7 \|x 1578-195X \|7 nnns
773	1	8	\|g volume:15 \|g year:2012 \|g number:7 \|g day:10 \|g month:11 \|g pages:535-540
856	4	0	\|u https://dx.doi.org/10.1007/s12094-012-0960-6 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 15 \|j 2012 \|e 7 \|b 10 \|c 11 \|h 535-540

Indexfelder

author_variant	t k tk s s ss u k uk e s es m c mc b o bo e y ey n y ny d a da o b ob n s ns s y sy a m am o p op f y fy o k ok m g mg n s t ns nst
matchkey_str	article:1578195X:2012----::oprsnfeodieramnotoebtenestvadercoymlcllncne
hierarchy_sort_str	2012
publishDate	2012
allfields	10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540
spelling	10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540
allfields_unstemmed	10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540
allfieldsGer	10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540
allfieldsSound	10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540
language	English
source	Enthalten in Revista de oncología 15(2012), 7 vom: 10. Nov., Seite 535-540 volume:15 year:2012 number:7 day:10 month:11 pages:535-540
sourceStr	Enthalten in Revista de oncología 15(2012), 7 vom: 10. Nov., Seite 535-540 volume:15 year:2012 number:7 day:10 month:11 pages:535-540
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Platinum sensitive disease Platinum refracter disease Second-line chemotherapy Small cell lung cancer
dewey-raw	610
isfreeaccess_bool	false
container_title	Revista de oncología
authorswithroles_txt_mv	Korkmaz, T. @@aut@@ Seber, S. @@aut@@ Kefeli, U. @@aut@@ Sari, E. @@aut@@ Canhoroz, M. @@aut@@ Oven, B. @@aut@@ Yildirim, E. @@aut@@ Yasar, N. @@aut@@ Aydin, D. @@aut@@ Balvan, O. @@aut@@ Sener, N. @@aut@@ Yuksel, S. @@aut@@ Mert, A. @@aut@@ Polat, O. @@aut@@ Yumuk, F. @@aut@@ Kanat, O. @@aut@@ Gumus, M. @@aut@@ Turhal, N. S. @@aut@@
publishDateDaySort_date	2012-11-10T00:00:00Z
hierarchy_top_id	385985452
dewey-sort	3610
id	SPR02426041X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02426041X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164619.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-012-0960-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02426041X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-012-0960-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Korkmaz, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum sensitive disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum refracter disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Small cell lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seber, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kefeli, U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sari, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canhoroz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oven, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildirim, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yasar, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aydin, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balvan, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sener, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuksel, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mert, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yumuk, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumus, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turhal, N. S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">15(2012), 7 vom: 10. Nov., Seite 535-540</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:7</subfield><subfield code="g">day:10</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:535-540</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-012-0960-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2012</subfield><subfield code="e">7</subfield><subfield code="b">10</subfield><subfield code="c">11</subfield><subfield code="h">535-540</subfield></datafield></record></collection>
author	Korkmaz, T.
spellingShingle	Korkmaz, T. ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
authorStr	Korkmaz, T.
ppnlink_with_tag_str_mv	@@773@@(DE-627)385985452
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1578-195X
topic_title	610 ASE Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213
topic	ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer
topic_unstemmed	ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer
topic_browse	ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista de oncología
hierarchy_parent_id	385985452
dewey-tens	610 - Medicine & health
hierarchy_top_title	Revista de oncología
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)385985452 (DE-600)2143451-7
title	Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
ctrlnum	(DE-627)SPR02426041X (SPR)s12094-012-0960-6-e
title_full	Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
author_sort	Korkmaz, T.
journal	Revista de oncología
journalStr	Revista de oncología
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2012
contenttype_str_mv	txt
container_start_page	535
author_browse	Korkmaz, T. Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S.
container_volume	15
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Korkmaz, T.
doi_str_mv	10.1007/s12094-012-0960-6
dewey-full	610
author2-role	verfasserin
title_sort	comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
title_auth	Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
abstract	Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
abstractGer	Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
abstract_unstemmed	Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	7
title_short	Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
url	https://dx.doi.org/10.1007/s12094-012-0960-6
remote_bool	true
author2	Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S.
author2Str	Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S.
ppnlink	385985452
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s12094-012-0960-6
up_date	2024-07-04T00:12:13.032Z
_version_	1803605175733059584
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02426041X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164619.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-012-0960-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02426041X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-012-0960-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Korkmaz, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum sensitive disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum refracter disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Small cell lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seber, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kefeli, U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sari, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canhoroz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oven, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildirim, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yasar, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aydin, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balvan, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sener, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuksel, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mert, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yumuk, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumus, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turhal, N. S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">15(2012), 7 vom: 10. Nov., Seite 535-540</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:7</subfield><subfield code="g">day:10</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:535-540</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-012-0960-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2012</subfield><subfield code="e">7</subfield><subfield code="b">10</subfield><subfield code="c">11</subfield><subfield code="h">535-540</subfield></datafield></record></collection>
score	7.3974905

Nicht das Richtige dabei?

Schreiben Sie uns!

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?